Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zarate

Showing results (561-570 of 606) with videos related to

Pageof 61
Sort By:
American Journal of Medical Genetics. Part A|December 5, 2012
Clinical utility of the X-chromosome arrayYuri A Zarate, Alka Dwivedi, Frank O Bartel, et al.
Nature|May 5, 2016
NMDAR inhibition-independent antidepressant actions of ketamine metabolitesPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Applications in Plant Sciences|May 5, 2016
Microsatellite primers for two threatened orchids in Florida: Encyclia tampensis and Cyrtopodium punctatum (Orchidaceae)Joanna Weremijewicz, Jasmin I Almonte, Vanessa S Hilaire, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2019
Antidepressant-relevant concentrations of the ketamine metabolite (2<i>R</i>,6<i>R</i>)-hydroxynorketamine do not block NMDA receptor functionEric W Lumsden, Timothy A Troppoli, Scott J Myers, et al.
Clinical Genetics|December 31, 2020
Growth, development, and phenotypic spectrum of individuals with deletions of 2q33.1 involving SATB2Yuri A Zarate, Katherine A Bosanko, Mary Ann Thomas, et al.
Eclinicalmedicine|October 12, 2023
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trialRavi Savarirayan, Daniel G Hoernschemeyer, Merete Ljungberg, et al.
The American Journal of Psychiatry|March 17, 2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and ImplementationRoger S McIntyre, Joshua D Rosenblat, Charles B Nemeroff, et al.
Nature Neuroscience|August 30, 2022
Experimenters' sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factorPolymnia Georgiou, Panos Zanos, Ta-Chung M Mou, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2023
Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world settingEdgar Carnero Contentti, Pablo A Lopez, Verónica Tkachuk, et al.
Brain : a Journal of Neurology|October 6, 2022
Loss-of-function variants in MYCBP2 cause neurobehavioural phenotypes and corpus callosum defectsLama AlAbdi, Muriel Desbois, Domniţa-Valeria Rusnac, et al.
Pageof 61

Showing results (561-570 of 606) with videos related to

Sort By:
Pageof 61
American Journal of Medical Genetics. Part A|December 5, 2012
Clinical utility of the X-chromosome arrayYuri A Zarate, Alka Dwivedi, Frank O Bartel, et al.
Nature|May 5, 2016
NMDAR inhibition-independent antidepressant actions of ketamine metabolitesPanos Zanos, Ruin Moaddel, Patrick J Morris, et al.
Applications in Plant Sciences|May 5, 2016
Microsatellite primers for two threatened orchids in Florida: Encyclia tampensis and Cyrtopodium punctatum (Orchidaceae)Joanna Weremijewicz, Jasmin I Almonte, Vanessa S Hilaire, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2019
Antidepressant-relevant concentrations of the ketamine metabolite (2<i>R</i>,6<i>R</i>)-hydroxynorketamine do not block NMDA receptor functionEric W Lumsden, Timothy A Troppoli, Scott J Myers, et al.
Clinical Genetics|December 31, 2020
Growth, development, and phenotypic spectrum of individuals with deletions of 2q33.1 involving SATB2Yuri A Zarate, Katherine A Bosanko, Mary Ann Thomas, et al.
Eclinicalmedicine|October 12, 2023
Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trialRavi Savarirayan, Daniel G Hoernschemeyer, Merete Ljungberg, et al.
The American Journal of Psychiatry|March 17, 2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and ImplementationRoger S McIntyre, Joshua D Rosenblat, Charles B Nemeroff, et al.
Nature Neuroscience|August 30, 2022
Experimenters' sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factorPolymnia Georgiou, Panos Zanos, Ta-Chung M Mou, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2023
Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world settingEdgar Carnero Contentti, Pablo A Lopez, Verónica Tkachuk, et al.
Brain : a Journal of Neurology|October 6, 2022
Loss-of-function variants in MYCBP2 cause neurobehavioural phenotypes and corpus callosum defectsLama AlAbdi, Muriel Desbois, Domniţa-Valeria Rusnac, et al.
Pageof 61